Statera BioPharma (STU:7CB) Days Payable: 4,228.45 (As of Sep. 2022) — 122% Above Median


What is Statera BioPharma Days Payable?

Statera BioPharma STU:7CB 20 Days Payable is 4,228.45 as of Sep. 2022, which is 122% above its 10-year median of 1,907.27. GuruFocus rates STU:7CB with a GF Score™ of 20/100. The stock has 1 warning sign investors should review.

Statera BioPharma's average Accounts Payable for the three months ended in Sep. 2022 was €7.92 Mil. Statera BioPharma's Cost of Goods Sold for the three months ended in Sep. 2022 was €0.17 Mil. Hence, Statera BioPharma's Days Payable for the three months ended in Sep. 2022 was 4,228.45.

The historical rank and industry rank for Statera BioPharma's Days Payable or its related term are showing as below:

STU:7CB' s Days Payable Range Over the Past 10 Years
Min: 1907.27   Med: 1907.27   Max: 1907.27
Current: 2004.9

During the past 3 years, Statera BioPharma's highest Days Payable was 1907.27. The lowest was 1907.27. And the median was 1907.27.

STU:7CB's Days Payable is not ranked
in the Biotechnology industry.
Industry Median: 113.56 vs STU:7CB: 2004.90

Statera BioPharma's Days Payable increased from Sep. 2021 (2,498.78) to Sep. 2022 (4,228.45). It may suggest that Statera BioPharma delayed paying its suppliers.

Statera BioPharma Days Payable Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma Days Payable Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Days Payable
0.00 0.00 1,876.54

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 2,498.78 862.58 1,369.18 3,303.97 4,228.45

STU:7CB vs NRBO, PALI, BLCM: Days Payable Comparison

For the Biotechnology subindustry, Statera BioPharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Statera BioPharma Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's Days Payable distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's Days Payable falls into.


Statera BioPharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Statera BioPharma's Days Payable for the fiscal year that ended in Dec. 2021 is calculated as

Days Payable (A: Dec. 2021 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2020 ) + Accounts Payable (A: Dec. 2021 )) / count ) / Cost of Goods Sold (A: Dec. 2021 )*Days in Period
=( (0.933 + 3.509) / 2 ) / 0.432*365
=2.221 / 0.432*365
=1,876.54

Statera BioPharma's Days Payable for the quarter that ended in Sep. 2022 is calculated as:

Days Payable (Q: Sep. 2022 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Jun. 2022 ) + Accounts Payable (Q: Sep. 2022 )) / count ) / Cost of Goods Sold (Q: Sep. 2022 )*Days in Period
=( (7.635 + 8.213) / 2 ) / 0.171*365 / 4
=7.924 / 0.171*365 / 4
=4,228.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 4,228.45 mean?
Statera BioPharma (STU:7CB) has a Days Payable of 4,228.45 as of Sep. 2022. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Statera BioPharma and its competitors. This is 122% above median its historical median of 1,907.27. Over the past decade, Statera BioPharma's Days Payable has ranged from 1,907.27 to 1,907.27.
Is Statera BioPharma's Days Payable too high?
Statera BioPharma's current Days Payable of 4,228.45 is 122% above median its 10-year median of 1,907.27. Over the past 10 years, this metric has ranged from a low of 1,907.27 to a high of 1,907.27. The Biotechnology industry median Days Payable is 113.56. Statera BioPharma's value of 4,228.45 is 3623.5% above this industry median. Overall, Statera BioPharma has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Statera BioPharma's Days Payable compare to NRBO and PALI?
Statera BioPharma's Days Payable of 4,228.45 can be compared against companies in the Biotechnology industry. The industry median Days Payable is 113.56. Statera BioPharma's value of 4,228.45 is 3623.5% above this benchmark. Historically, Statera BioPharma's own Days Payable has ranged from 1,907.27 to 1,907.27 over the past decade. While the company's 10-year median is 1,907.27 vs. the industry median of 113.56, Statera BioPharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Statera BioPharma's current Days Payable of 4,228.45 is 3623.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Statera BioPharma and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Statera BioPharma's current Days Payable is 4,228.45, which is 122% above median its own 10-year median of 1,907.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (STU:7CB) has a current Days Payable of 4,228.45. The current Days Payable is 4,228.45, which is 122% above median its 10-year median of 1,907.27 and 3623.5% above the Biotechnology industry median of 113.56. Statera BioPharma's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Statera BioPharma (STU:7CB), the current Days Payable is 4,228.45 as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.